Additional possibilities of bioregulation products in correction of ENT-associated halitosis (bad smelling breath)

Chronic tonsillitis is a very common disease, often occurs in patients with somatic pathology, such as enterocolitis against the background of lactase deficiency, diabetes, kidney disease. Chronic tonsillitis is accompanied by halitosis, and with comorbidities, this symptom may become dominant. With exacerbation of chronic tonsillitis, patients are forced to increase the drug load, which is due to concomitant somatic diseases. To prevent polypragmasy, doctors more often began to turn to modern means of bioregulatory therapy, providing detoxification and anti-inflammatory effects. Of the diseases of the internal organs, giving an unpleasant smell from the mouth, in the first place is diabetes. Treatment of diabetes, especially in the newly ill, takes a lot of time and effort, and a more rapid deposition of plaque and the formation of tartar in violation of microcirculation and deterioration of tissue supply, including in the oral cavity and pharynx, contributes to halitosis. The appearance of an unpleasant odor in diseases of the kidneys, liver, endocrine system, intestines in exhaled air, due to metabolites in the blood, is persistent and does not respond well to correction. In this regard, the search for detoxification drugs is relevant. Having studied the pharmacodynamic capabilities of the drug Engystol we paid attention to its ability to improve the condition of patients with viral infections, allergic reactions, restore metabolic processes in tissues, maintain general homeostasis. Unlike many drugs that have a toxic effect on the liver, this bioregulatory drug is safe.

tonsillitis, diabetes mellitus, lactase deficiency, drug therapy, Engystol